MedPath

Porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with advanced or metastatic cholangiocarcinomas and other biliary tract tumours: a multicentre, randomised, phase lll study - PHOTOSTENT-02

Phase 1
Conditions
Advanced or metastatic cholangiocarcinomas and other biliary tract tumours
Registration Number
EUCTR2005-001173-96-GB
Lead Sponsor
niversity College London
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
Not specified
Target Recruitment
240
Inclusion Criteria

Histological/cytological confirmation of disease, not suitable for surgery, adequate biliary drainage, ECOG performance status 0, 1, 2 or 3 , life expectancy > 3 months, patient consent, age > or = 18 years
(In addition patients whose histology/cytology which is highly suspicious for malignancy in conjunction with a clinical diagnosis of biliary tract cancer (inclusing evidence of a mass lesion), may be included in the study at the TMG's decision.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Concurrent treatment for metastatic disease, other/prior malignancy or intercurrent disease, prophyria, unfit for endoscopy, pregnancy/lactation, unable to give consent

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: To determine whether profimer sodium photodynamic therapy (PDT), in addition to standard treatment, confers an overall survival benefit in patients with advanced, non-resectable biliary tract carcinoma;Secondary Objective: To determine progression-free survival, toxicity and quality of life;Primary end point(s): Overall survival
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath